REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio total assets
Total assets on the balance sheet at the end of each period.
Regenxbio's total assets was $386.62M at Jun 30, 2026. For fiscal 2025 it was $453.03M, down 2.8% from the year before. Over ten years it grew 7.4% a year on average. The highest annual figure on record is $1.11B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $453.03M | -2.8% |
| FY2024 | Dec 31, 2024 | $465.99M | -18.8% |
| FY2023 | Dec 31, 2023 | $573.97M | -31.1% |
| FY2022 | Dec 31, 2022 | $833.27M | -25.2% |
| FY2021 | Dec 31, 2021 | $1.11B | +57.3% |
| FY2020 | Dec 31, 2020 | $708.16M | +42.2% |
| FY2019 | Dec 31, 2019 | $497.91M | -8.4% |
| FY2018 | Dec 31, 2018 | $543.81M | +173.7% |
| FY2017 | Dec 31, 2017 | $198.68M | +15.0% |
| FY2016 | Dec 31, 2016 | $172.73M | -22.0% |
| FY2015 | Dec 31, 2015 | $221.38M | +6241.4% |
| FY2014 | Dec 31, 2014 | $3.49M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $386.62M | -33.5% |
| Q1 FY2026 | Mar 31, 2026 | $341.89M | -30.4% |
| Q4 FY2025 | Dec 31, 2025 | $453.03M | -2.8% |
| Q3 FY2025 | Sep 30, 2025 | $525.20M | +1.2% |
| Q2 FY2025 | Jun 30, 2025 | $581.03M | +2.0% |
| Q1 FY2025 | Mar 31, 2025 | $490.93M | -22.0% |
| Q4 FY2024 | Dec 31, 2024 | $465.99M | -18.8% |
| Q3 FY2024 | Sep 30, 2024 | $519.11M | -18.1% |
| Q2 FY2024 | Jun 30, 2024 | $569.38M | -16.6% |
| Q1 FY2024 | Mar 31, 2024 | $629.22M | -15.9% |
| Q4 FY2023 | Dec 31, 2023 | $573.97M | -31.1% |
| Q3 FY2023 | Sep 30, 2023 | $633.79M | -28.3% |
| Q2 FY2023 | Jun 30, 2023 | $682.46M | -28.4% |
| Q1 FY2023 | Mar 31, 2023 | $747.83M | -27.1% |
| Q4 FY2022 | Dec 31, 2022 | $833.27M | -25.2% |
| Q3 FY2022 | Sep 30, 2022 | $883.79M | +10.4% |
| Q2 FY2022 | Jun 30, 2022 | $953.44M | +14.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.03B | +16.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.11B | +57.3% |
| Q3 FY2021 | Sep 30, 2021 | $800.40M | +47.9% |
| Q2 FY2021 | Jun 30, 2021 | $836.40M | +86.0% |
| Q1 FY2021 | Mar 31, 2021 | $879.44M | +89.6% |
| Q4 FY2020 | Dec 31, 2020 | $708.16M | +42.2% |
| Q3 FY2020 | Sep 30, 2020 | $541.17M | +6.3% |
| Q2 FY2020 | Jun 30, 2020 | $449.74M | -15.0% |
| Q1 FY2020 | Mar 31, 2020 | $463.94M | -10.6% |
| Q4 FY2019 | Dec 31, 2019 | $497.91M | -8.4% |
| Q3 FY2019 | Sep 30, 2019 | $509.24M | -1.1% |
| Q2 FY2019 | Jun 30, 2019 | $529.14M | +57.5% |
| Q1 FY2019 | Mar 31, 2019 | $519.03M | +63.6% |
| Q4 FY2018 | Dec 31, 2018 | $543.81M | +173.7% |
| Q3 FY2018 | Sep 30, 2018 | $514.98M | +146.1% |
| Q2 FY2018 | Jun 30, 2018 | $335.99M | +49.7% |
| Q1 FY2018 | Mar 31, 2018 | $317.22M | +41.5% |
| Q4 FY2017 | Dec 31, 2017 | $198.68M | +15.0% |
| Q3 FY2017 | Sep 30, 2017 | $209.26M | +6.8% |
| Q2 FY2017 | Jun 30, 2017 | $224.38M | – |
| Q1 FY2017 | Mar 31, 2017 | $224.13M | – |
| Q4 FY2016 | Dec 31, 2016 | $172.73M | – |
| Q3 FY2016 | Sep 30, 2016 | $195.98M | – |
See a number that looks wrong?